ProKidney Corp.

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%
HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

At a Glance

Live Snapshot
Market Cap$581.72M
EPS-0.5200
P/E Ratio-3.33
Earnings Date08/06/2026

prok

Other Payables

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

ProKidney Corp.

ProKidney Corp. Competitors Analysis of Other Payables

PROK · NASDAQ
CompanyOther Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A 
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
0.00
N/AN/AN/A
239.00K
N/AN/AN/A
0.00
N/AN/AN/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
0.00
N/AN/AN/A
0.00
N/AN/AN/A
ANAB logo
AnaptysBio, Inc.
NASDAQ:ANAB
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
0.00
N/AN/AN/A
0.00
N/AN/AN/A
XNCR logo
Xencor, Inc.
NASDAQ:XNCR
3.59M
-14.7%N/AN/A
ProKidney Corp.

ProKidney Corp. Fair Value Envelope

PROK · NASDAQ

Our analysis suggests that PROK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.73, this represents a potential HIDDEN relative to our calculated worth for ProKidney Corp..

Intrinsic Value
Current Price: $1.73